We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Powered Blood Test Enables Detection, Analysis and Profiling of Cancer Tumors

By LabMedica International staff writers
Posted on 10 Dec 2024
Print article
Image: The new method will help guide cancer treatment using blood samples (Photo courtesy of 123RF)
Image: The new method will help guide cancer treatment using blood samples (Photo courtesy of 123RF)

Mutational signatures are changes in DNA patterns caused by cancer’s effects on cells in the body. These signatures can provide valuable insights into the cancer, such as the potential causes behind its development and which therapies may be most effective. Currently, obtaining this information requires whole genome sequencing of a tissue biopsy from the cancer, which is then compared to the patient's matched normal DNA sample. A standard biopsy that involves removing tissue or cells is costly and time-consuming, and it can also be difficult to collect tissue biopsy samples, especially when the tumor is located in hard-to-reach areas.

Researchers at Peter MacCallum Cancer Centre (Victoria, Australia) have now developed a method that utilizes circulating tumor DNA (ctDNA) from a patient's blood to detect cancer-related DNA changes. Their innovative approach, known as MisMatchFinder, uses an algorithm to identify these changes through a simple blood test. This method, published in Nature Communications, offers the potential to make genome sequencing more accessible and efficient, enabling quicker, personalized treatment plans for cancer patients. Moreover, it could revolutionize cancer monitoring by tracking changes in the disease over time, eliminating the need for repeated biopsies.

“Excitingly, this new methodology will allow us to observe what is happening to the tumor over various time points,” said study co-author Dr. Dineika Chandrananda. “MisMatchFinder brings considerable advances to the clinic and holds the potential to provide new insights into the use of mutational signatures. We believe that this knowledge will help guide and inform clinical decisions to optimize research led cancer treatment strategies.”

New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
New
Borrelia Burgdorferi Test
AESKULISA Borrelia-M
New
RNA/DNA Extraction Instrument
QIAcube Connect Instrument

Print article

Channels

Microbiology

view channel
Image: The breakthrough system offers a faster way to diagnose bloodborne infections (Photo courtesy of Melio)

Culture-Free Platform Rapidly Identifies Blood Stream Infections

Neonatal sepsis is a life-threatening condition that results from bloodstream infections in newborns under 28 days old. Due to their immature immune systems, newborns are especially vulnerable to infections.... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.